Minimal-Dose Cancer Chemotherapy: Anti-Cancer Drugs Loaded Nanodevices towards Time, Site Organ-Specific Releases for Development of Personalized Nanomedicine

机译：最小剂量的癌症化学疗法：针对时间，部位和器官的特定释放，抗癌药物装载了纳米器件，用于开发个性化纳米医学。

获取原文

页面导航

摘要
著录项
相似文献
相关主题

摘要

An attempt to design a site-directed, organ-targeting, time-maneuvered, controlled drug delivery nanodevice was undertaken. The anti-cancer drug methotrexate loaded nanovesicles of human serum protein albumin, surface-functionalized with tumor-affinity protein avidin, for treatment of human mammary gland carcinoma were prepared. The formulation was designed for a minimum dose requirement with predictable span of delivery and fixed-frequency of administration towards a goal for developing personalized nanomedicine suitable for individually defined medication requirements.

机译：进行了设计定点，器官靶向，时间操纵，可控制的药物输送纳米装置的尝试。制备了载有抗肿瘤药甲氨蝶呤的人血清蛋白白蛋白纳米囊泡，用肿瘤亲和蛋白亲和素进行表面功能化处理，用于治疗人乳腺癌。该制剂被设计用于最小剂量要求，具有可预测的递送跨度和固定的给药频率，以达到开发适合个体定义的药物需求的个性化纳米药物的目标。

著录项

来源
《NSTI-Nanotech 2010;NSTI nanotechnology conference and expo;Bio Nanotech 2010;NSTI bio nano conference and expo;Microtech 2010;Microtechnology conference and expo;WCM 2010;Workshop on compact modeling;NSTI nanotech ventures;TechConnect summit;Clean technology》|2010年|P.397-400|共4页
会议地点
作者
Riaz A. Khan; Shilpa J. Newati; Varsha M. Singh; Sarita Sachdeva; Rakesh Sharma;
展开▼
作者单位

展开▼
会议组织
原文格式 PDF
正文语种
中图分类特种结构材料;
关键词
personalized nanomedicine; site organ specific deliveries; minimal dose cancer chemotherapy; methotrexate; breast cancer;

机译：个性化纳米医学;特定地点和器官的交付;小剂量癌症化学疗法;甲氨蝶呤乳腺癌;

相似文献

外文文献
专利

1. MSN Anti-Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition [J] . Qianjun He, Jianlin Shi Advanced Materials . 2014,第3期

机译：MSN抗癌纳米药物：增强化学疗法，克服耐药性和抑制转移
2. Therapeutic polymeric nanomedicine: GSH-responsive release promotes drug release for cancer synergistic chemotherapy [J] . RSC Advances . 2019,第64期

机译：治疗聚合物纳米杂种：GSH响应释放促进癌症协同化疗的药物释放
3. Therapeutic polymeric nanomedicine: GSH-responsive release promotes drug release for cancer synergistic chemotherapy [J] . Jie Shen, Qiwen Wang, Jie Fang, RSC Advances . 2019,第64期

机译：高分子纳米药物的治疗：GSH响应释放促进癌症协同化疗的药物释放
4. Minimal-Dose Cancer Chemotherapy: Anti-Cancer Drugs Loaded Nanodevices towards Time, Site Organ-Specific Releases for Development of Personalized Nanomedicine [C] . Riaz A. Khan, Shilpa J. Newati, Varsha M. Singh, NSTI Nanotechnology Conference Expo . 2010

机译：Minimal-Dose癌症化疗：抗癌药物负载纳米型，朝向时间，场地和器官特定发布，用于开发个性化纳米医疗
5. Development of NIPAAM-based thermosensitive, injectable and biodegradable copolymers for controlled release of anti-cancer drug. [D] . Cui, Zhanwu. 2009

机译：基于NIPAAM的热敏，可注射和可生物降解的共聚物的开发，用于控制抗癌药物的释放。
6. Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting [O] . Wei Zhang, Shi-Yuan Cheng, Li-Fang Hou, 2014

机译：个性化癌症药物的基因组学及其对中国早期药物开发的影响：美国中国抗癌协会第六届年会在第50届ASCO年会上的报告
7. Therapeutic polymeric nanomedicine: GSH-responsive release promotes drug release for cancer synergistic chemotherapy [O] . Jie Shen, Qiwen Wang, Jie Fang, 2019

机译：治疗聚合物纳米杂种：GSH响应释放促进癌症协同化疗的药物释放

Minimal-Dose Cancer Chemotherapy: Anti-Cancer Drugs Loaded Nanodevices towards Time, Site Organ-Specific Releases for Development of Personalized Nanomedicine

摘要

著录项

相似文献

相关主题

期刊订阅